infusions in patients relapsing with chronic myeloid leukaemia (CML) 8, 9 and other haematological malignancies 10-14 following BMT.
which was fatal in one patient. Chronic GVHD was observed in most patients, although with minimal overIn 1992, our unit embarked on a phase II study of rapidly tapering CYA between days 30 and 60, in an attempt to all impact on performance status. The overall probability of survival at 2 years was 43%. This nonharness a possible graft-versus-tumour effect in high-risk transplant recipients. The primary aim was to evaluate the randomised experience indicates that a rapid taper of CYA is tolerable and may provide an alternative to tolerability of this approach, in particular, the subsequent incidence and severity of acute and chronic GVHD and the immunotherapy with donor leukocyte infusion in the high-risk allograft setting.
response of GVHD to treatment. A secondary intention was to make a preliminary assessment of the clinical utility of Keywords: cyclosporine; taper; high risk; allograft this approach by evaluating the disease-free survival of the study group.
Disease recurrence after allogeneic BMT is a common cause of therapeutic failure in patients with advanced Methods haematological malignancy. In the absence of GVHD, the likelihood of relapse following transplantation from HLAFifty-eight consecutive patients considered at high risk of identical siblings approaches 80% in patients transplanted relapse who underwent BMT at the Royal Melbourne Hosduring first relapse. 1 Efforts to improve survival rates pital between January 1992 and September 1996 were elithrough intensification of conditioning regimens have gible for analysis. All patients received HLA-identical siblargely been unsuccessful. 2 ling transplants other than one who received marrow from There are substantial animal data demonstrating the presan HLA-matched aunt. High risk was defined as: acute ence of a graft-versus-leukaemia (GVL) effect. 3, 4 Until myeloid leukaemia (AML) beyond first CR (CR1), acute recently however, evidence for a GVL effect in humans lymphoblastic leukaemia (ALL) beyond CR1 or in CR1 has been largely indirect. 5 Large retrospective studies from with adverse cytogenetics (t(9;12), hypodiploid or monoSeattle and the International Bone Marrow Transplant somy 7), CML in accelerated phase (AP) or blast crisis Registry demonstrated increased relapse rates in patients (BC), refractory anaemia with excess blasts in transformwho did not develop GVHD following BMT or in those ation (RAEB-T), secondary AML, myelofibrosis, multiple who received T cell-depleted allografts. 6 received a gradual CYA taper. Eight of these patients did not subsequently develop acute GVHD. Another four patients had pre-existing mild GVHD (grade I) involving infusion on the day prior to BMT. Oral CYA 6 mg/kg/day skin only and were tapered without exacerbation of their was introduced once oral intake was satisfactory.
GVHD. The remaining four patients developed Ͼgrade II A gradual CYA taper (reduced by approximately 100 acute GVHD (III = 2, IV = 2) a median of 12 days (range mg/week) was commenced on day +30 in patients who had 3-31) after cessation of CYA. One patient with grade III not experienced significant acute GVHD (defined as у GVHD (skin and liver) was not treated with steroids; the grade II) and whose day 28 marrow was in remission. If other was successfully treated with methylprednisolone. no GVHD subsequently developed, the CYA was ceased Both patients with grade IV GVHD received intravenous by day 60. In those patients with evidence of persistent CYA and methylprednisolone after initial failure of oral malignancy on an early post-transplant marrow examincorticosteroids. No patient in this group died from severe ation (generally day 28, but ranging between days 14 and acute GVHD. 50), CYA was usually stopped over a number of days rather Ten patients had a very rapid taper performed due to than weeks. If acute GVHD occurred while tapering took persistent disease on an early post-transplant marrow examplace, the CYA was continued at its current dose or predniination (n = 9) or CYA neurologic toxicity (n = 1). The solone was added. In the event of more severe GVHD, an median time the taper was commenced was day 40 (range increased dose of CYA was given together with pulse intra-14-50). One of these patients subsequently failed to venous methylprednisolone 2-3 mg/kg/day. Severe uncondevelop any acute GVHD. Another five patients had grade trolled GVHD required hospitalisation, delivery of intra-I GVHD at the time of taper, but none developed worsening venous CYA, and in some instances, antithymocyte acute GVHD. One patient developed grade II acute GVHD globulin (ATGAM).
30 days after completion of his taper and subsequently died from extensive chronic GVHD with underlying disease Measures of outcome relapse. The remaining three patients developed grade IV Formal evaluations were performed on all patients at 1, 3, 6 and 12 months post-BMT and annually thereafter. In patients surviving beyond 6 months.
Acute and chronic GVHD were diagnosed and graded acute GVHD after completion of the taper. One of these patients had his CYA abruptly stopped on the assumption of morphological relapse which was not confirmed cytogenetically. He developed severe hyperacute GVHD 7 days later which did not respond to methylprednisolone, ATGAM and tacrolimus and he died in CR on day 107. The other two individuals developed severe GVHD 10 and 25 days, respectively, after cessation of CYA. One responded rapidly to a single course of pulse methylprednisolone, while the other required intravenous CYA and methylprednisolone to establish control of GVHD. Fourteen of the 18 tapered patients surviving longer than 6 months have developed chronic GVHD (limited = 7, extensive = 7). Eleven of these patients remain alive beyond 6 months, of whom the seven in CR all have chronic GVHD. One patient in CR died from sepsis in the context of severe chronic GVHD.
Non-tapered patients: Twenty-three patients were unable to undergo tapering due to acute GVHD manifesting prior to day +30. Two patients developed grade III GVHD and three developed grade IV GVHD. Twelve patients were given intravenous methylprednisolone, two of whom required ATGAM because of steroid-resistant GVHD. The remaining 11 patients were successfully treated with CYA and oral steroids. Fifteen patients have survived beyond 6 months, in whom no, limited and extensive chronic GVHD has developed in one, two and 12 patients, respectively.
Overall, 28 of 33 survivors beyond 6 months developed Twelve of the 23 patients who were not tapered due to significant pre-existing GVHD remain alive and diseasefree at a median follow-up of 70 weeks (range 26-139).
was analysed the median survival was 52 weeks (range 4-140), and the probability of surviving 1 year was 64 Ϯ 11% One patient in this group remains alive with stable disease, and the rest died of GVHD in the setting of relapse (two and 2 years 57 Ϯ 12%. The median disease-free survival was 20 weeks (range patients), GVHD in CR (one patient), sepsis in CR (one patient) and relapse alone (six patients).
0-240) with a median of 68.5 weeks (range 9-240, mean = 87) in the patients tapered in CR and without early The median survival of the entire 58 patients was 31.5 weeks (range 3-240). The overall probability of surviving GVHD, and a median of 27 weeks (range 4-139, mean = 46) in the patients not tapered due to GVHD. These values at 2 years was 43 Ϯ 8% and at 3 years was 38 Ϯ 8% (Figure 2) . When the sub-group of 18 patients with AML
were not statistically different (P = 0.23). Figure 3 illustrates the overall survival of the four disand short-course methotrexate prophylaxis with CYA continued for 6 months post-transplant. 18, 21 The patients who tinct groups of patients: those tapered because of persistent disease, those tapered in CR, patients not tapered because were tapered abruptly because of persistent disease at day 28 did not appear to experience a higher rate of acute of early acute GVHD and the patients who died of regimenrelated toxicity. A log-rank analysis demonstrated no sig-GVHD than the more gradually tapered group, although when GVHD occurred it tended to be more severe (three nificant difference in overall survival between tapered and non-tapered patients (P = 0.13).
of 10 patients with grade IV GVHD, fatal in one). Given the potential for developing fatal acute GHVD, caution is required before instituting an abrupt early taper and in partiGraft-versus-tumour effect cular, certainty of persistent disease at the time is required. It could be proposed that the onset of acute GVHD There were four patients in whom an apparent graft-versustumour response was observed. One patient with a lowwithin the first month post-transplant may exert a greater GVL effect and improve disease-free survival in comparigrade lymphoma had persistent radiological and bone marrow disease evident at day 30. Following a rapid CYA taper son with the delayed onset of GVHD after a rapid CYA taper. While our study failed to demonstrate this, the numhe developed grade IV acute GVHD, after which there was substantial clearing of his marrow involvement and ber of patients in each group was insufficient to reveal statistically significant differences. Therefore, we have avoided reduction in lymphadenopathy. He is currently in a CR at 20 months post-transplant with extensive chronic GVHD.
overinterpreting any comparison of disease-free or overall survival between tapered and non-tapered patients. In this One patient with multiple myeloma had a persistent marrow plasmacytosis and paraprotein at day 30, which disappeared context, it is important to note that chronic GVHD may have a more powerful antileukaemic effect than acute following withdrawal of his CYA and induction of grade IV acute GVHD. A third patient with a rapidly growing GVHD.
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Of interest is our observation that the vast majority of lymphomatous mediastinal mass post-transplant and consolidation radiotherapy, had all immunosuppression ceased.
both the tapered and non-tapered patients surviving beyond 6 months developed chronic GVHD. The incidence also The mass subsequently resolved and she currently remains in remission 41 weeks post-BMT, despite not developing appears higher than the approximately 50% observed in patients receiving 6 months of CYA. 18, 21 Although one overt evidence of GVHD. A fourth patient with AML had a taper performed because of relapse. He developed fatal patient in remission died from chronic GVHD, the overall morbidity from chronic GVHD appears to be acceptable, acute GVHD and at autopsy was found to have no evidence of persistent disease.
with the median Karnofsky score of both tapered and nontapered survivors being approximately 80%. There is preliminary evidence in this non-randomised study to suggest that an early CYA taper may elicit a cliniDiscussion cally beneficial graft-versus-tumour effect. The four cases described earlier are consistent with this. The overall probThe results of this study confirm that an early CYA taper policy can be used with reasonable safety in a high-risk ability of survival at 2 years is 43%. The probability of survival at 2 years in the sub-group of patients transplanted population undergoing allogeneic BMT. The overall incidence of grade III-IV GVHD in the tapered patients (27%) for AML in first relapse (57 ± 12%) compares favourably with a reported 2 year survival of approximately 35% in appears higher than that reported in patients receiving CYA similar patients treated with a variety of GVHD prophylaxis regimens. 23 While these results are encouraging, caution must be used in their interpretation as the patient population is heterogenous and numbers relatively small.
Another immunomodulatory strategy currently under investigation is the reinfusion of donor leukocytes posttransplant in patients without GVHD; thus far, this has largely been confined to recipients of T cell-depleted marrow. [24] [25] [26] Another variation in this method could be the use of partial T cell-depletion in combination with a rapid CYA taper. In contrast, in patients at high risk of relapse a strategy of using T cell-replete marrow but reducing the total CYA dose by either lowering the initial infusional dose, 16 or tapering early, represents a logistically easier approach. The ultimate effect, however, of these approaches on morbidity from GVHD and on relapse-free survival, will need to be evaluated in prospective randomised trials. 
